Altre lingue Immutep ADR Nasdaq

Azioni

IMMP

US45257L1089

Tempo reale stimato Cboe BZX Altri mercati azionari 17:31:59 12/07/2024			Variaz. 5gg	Var. 1 gen.
2,265 ^USD	+12,69%		+17,05%	-5,38%

15:28	Aggiornamento settoriale: i titoli del settore sanitario sono stati misti venerdì prima del mercato	MT
15:23	Aggiornamento settoriale: Assistenza sanitaria	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sector Update: Health Care Stocks Mixed Premarket Friday	15:28
Sector Update: Health Care	15:23
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Friday as Big Bank Earnings Kick Off Earnings Season	14:44
Top Premarket Gainers	13:49
Immutep Achieves 'Positive' Results From Cohort B of Phase 2B Cancer Trial; Shares Rise Pre-Bell	11:15
Rising US Rate Cut Bets Lift Australian Shares to Record High	08:47
Immutep Surges 19% Following Positive Results in Head, Neck Cancer Trial	06:53
Immutep : Global Webcast Slides for TACTI 003 Positive Data in Patients with Negative PD L1 Expression (Cohort B)	01:15
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	00:41
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression	00:40
Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results	03/07
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	28/06
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	28/06
ADRs End Flat; Alarum Technologies Climbs 26%	27/06
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	27/06
Immutep Reports Positive Results in Drug Combination Trial for Head, Neck Cancer	27/06
Immutep Limited (IMM) \| TACTI-003: the real results; Maintain Overweight A$1.13 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)	27/06
Immutep : Global Webcast Slides for New Efti Clinical Data in 1st Line HNSCC	27/06
Immutep Gets Exclusive Rights to Develop, Commercialize New Anti-LAG-3 Small Molecules	25/06
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer	25/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Immutep ADR Nasdaq

Azioni

IMMP

US45257L1089

Altre lingue

Filtri